AI-generated summary
This protocol describes a planned randomised, double-blind trial of photobiomodulation before rhinoplasty, comparing active treatment with sham treatment in 60 participants. The primary outcome is periorbital oedema on postoperative day 3, and results have not yet been reported. The authors state that the study was approved by an ethics committee and registered at ClinicalTrials.gov.
- Participants
- 60
- Who or what was studied
- Individuals undergoing rhinoplasty at a single centre in São Paulo, Brazil
- Wavelengths
- 660, 808 nm
- Limits stated in the abstract
- This is a study protocol only, so no efficacy results are reported and the findings are unknown.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 808 nm
- Power
- 150 mW
- Total energy
- 12 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Sham, Visual analogue scale, Trial registration, Primary outcome, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.